Recent Updates
Recently added Catalysts
PFE Positive Sentiment

Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026

Saturday, October 24, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Pfizer reported positive Phase 2 results for its 25-valent pneumococcal vaccine candidate, PF-07872412. The study demonstrated strong immune responses across all 25 serotypes in infants. Additionally, the vaccine showed safety and tolerability similar to the existing PREVNAR 20® vaccine. These findings were presented at IDWeek 2026.

Market Sentiment Analysis

POSITIVE FACTORS

  • Robust immune responses against all 25 serotypes.
  • Safety and tolerability comparable to PREVNAR 20®.
  • Detailed results presented at IDWeek 2026.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+29%
120-day peak, hindsight
Typical move
1.4%
average across 15 past catalysts
Lead asset
Ibuzatrelvir co-process API film coated
Phase 1 · Coronavirus Disease 2019

Full Press Release Details

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results across serotypes from a Phase 2 study (NCT06524414) for its investigational 25-valent pneumococcal conjugate vaccine candidate, PF-07872412 (25vPnC), in infants. In the study, a four-dose series of 25vPnC elicited robust immune responses against all 25 serotypes and showed safety and tolerability comparable to four doses of PREVNAR 20® (Pneumococcal 20-valent Conjugate Vaccine). These findings were shared today

Frequently Asked Questions

What is the 25-valent pneumococcal vaccine?

It is Pfizer's investigational vaccine candidate, PF-07872412.

What were the results of the Phase 2 study?

The study showed robust immune responses and comparable safety.

How many serotypes does the vaccine target?

The vaccine targets 25 different serotypes.

Where were the findings presented?

The findings were shared at IDWeek 2026.

ShareAdd on Google
Tags: PFE Pfizer PF-07872412 pneumococcal vaccine Phase 2 study IDWeek 2026
Last updated: Oct 24, 2026

Biotech snapshot

Cash runway
$11699M liquidity · $0M/mo burn
Low dilution risk
Lead asset
Ibuzatrelvir co-process API film coatedPhase 1
Coronavirus Disease 2019 →

Catalyst track record

+29%
best trade around PFE's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for PFE.

See every catalyst's timing & PoA →